title: rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates LPS-induced acute lung injury in mice by inhibiting neutrophil migration.
abstract: The binding of selectin to P&mdash;selectin glycoprotein ligand&mdash;1 (PSGL&mdash;1) mediates the tethering and rolling of leukocytes on the endothelium during leukocyte migration and inflammation. Recombinant human PSGL&mdash;1&mdash;Ig fusion protein (rPSGL&mdash;1&mdash;Ig) is a widely used selectin inhibitor that prevents neutrophil entry into inflamed or reperfused tissues. We hypothesized that rPSGL&mdash;1&mdash;Ig could be used to as a drug for the treatment of acute lung injury (ALI). We induced murine ALI by injecting mice with lipopolysaccharide (LPS) and then treated the mice with rPSGL&mdash;1&mdash;Ig. We determined the lung injury index, wet/dry ratio, and inflammatory cytokine level in differentially treated mice. The symptoms of LPS&mdash;induced lung injury were alleviated by rPSGL&mdash;1&mdash;Ig treatment. The histopathological index of LPS&mdash;induced lung injury improved after rPSGL&mdash;1&mdash;Ig treatment. rPSGL&mdash;1&mdash;Ig treatment also reduced the recruitment of inflammatory cells, including neutrophils, into the lung, as well as reducing the level of inflammatory cytokines. These data suggest that rPSGL&mdash;1&mdash;Ig protein has a therapeutic effect on LPS&mdash;induced lung injury.
authors: Henan Provincial People&apos;s Hospital Zhengzhou China.
authors: H-Z
authors: HZ
authors: Shao
authors: Henan Provincial People&apos;s Hospital Zhengzhou China qinbyu424&commat;126.com.
authors: B-Y
authors: BY
authors: Qin
mesh_terms: D055371:Acute Lung Injury / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control*; D000818:Animals; D018893:Bronchoalveolar Lavage; D002452:Cell Count; D002465:Cell Movement / Q000187:drug effects* / Q000502:physiology; D004195:Disease Models, Animal; D005260:Female; D007074:Immunoglobulin G / Q000494:pharmacology*; D015850:Interleukin-6 / Q000378:metabolism; D008070:Lipopolysaccharides / Q000009:adverse effects*; D008562:Membrane Glycoproteins / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL; D009504:Neutrophils / Q000187:drug effects / Q000473:pathology*; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D011994:Recombinant Proteins / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D007074:Immunoglobulin G; D015850:Interleukin-6; D008070:Lipopolysaccharides; D008562:Membrane Glycoproteins; C084882:P-selectin ligand protein; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha